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Perspectives of vaccination in Chagas disease revisited
Erney Plessmann Camargo
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The perspectives for a Chagas Disease vaccine 30 years ago and today are compared. Antigens and adjuvants 
have improved, but logistic problems remain the same. Sterilizing vaccines have not been produced and animal mod-
els for chronic Chagas have not been developed. Vector control has been successful and Chagas incidence has come 
to a halt. We do not have a population candidate to vaccination now in Brazil. And if we had, we would not know 
how to evaluate the success of vaccination in a short time period. A vaccine may not seem important at the moment. 
However, scientific reasons and incertitudes about the future recommend that a search for a vaccine be continued. 
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In 1982, Carlos Chagas Filho, then President of the 
Academy of Sciences of the Vatican, invited Zigman 
Brener and myself to present, at a meeting celebrating 
the historical rehabilitation by the Church of Galileo 
Galilei, a paper about the “Perspectives of vaccination in 
Chagas disease” (Brener & Camargo 1982).  At one ses-
sion of this memorable meeting, physicists and astrono-
mers gathered to discuss the Big Bang and, at another, 
Black Holes. At our session, researchers were asked to 
present their views on vaccines against parasitic diseas-
es. After the seminal work of Ruth Nussenzweig on the 
protective potentialities of the circumsporozoite protein 
of plasmodia, we were quite confident that antiparasitic 
vaccines would soon be produced. These were days of 
great hope and optimism, and optimistic we were, my 
late friend Brener and I.
However, to avoid uncritical optimism, before writ-
ing our paper we decided to ask ourselves a few ques-
tions and to answer them impartially. I jotted down and 
kept our preliminary reflections. The paper presented at 
the Vatican session did not follow the order of the script. 
We were not bound to that script. We were simply ask-
ing and answering the questions that we candidly for-
mulated to ourselves as a brainstorming exercise, not as 
a paper draft. Now, with three decades gone by, I think 
that it is worth comparing the “perspectives” as we saw 
them in 1982 and as I see them now. The questions that 
we formulated to ourselves were:
Question 1 - Are we going to have a vaccine against 
Chagas disease in 20 years’ time?
The answer was no. Not then, not now. We submit-
ted at the meeting that the logistics involved in finding 
protective antigens and to proceed from them to produce 
and test a Chagas vaccine in field conditions (see Ques-
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tion 3) would require more than 20 years, even if we al-
ready had a “miracle antigen” at hand. Unfortunately, 
to complicate the matter of a Chagas vaccine, we were 
disappointed by the fact that a much acclaimed and sup-
posedly protective surface protein of Trypanosoma cruzi 
had just turned out to be an artefact, not the acclaimed 
“miracle antigen” (Camargo et al. 1982). Three decades 
later, no such “miracle antigen” of T. cruzi has been pro-
posed and no way has been found to shorten the time 
necessary to test a vaccine in humans. We are where we 
were 30 years ago.
Question 2 - If the vaccine is not coming soon, what 
could we do in the meantime to fight Chagas disease? 
 
We summarily dismissed clinical treatment as a 
form of controlling Chagas. We also did not think that 
transmission through blood transfusion was an unsolv-
able problem and anticipated that legislation and techni-
cal improvements would bring transfusive Chagas to a 
halt. This is happening (Moncayo 2003). As for vertical 
transmission between mother and newborn, we could 
not foresee a solution. I still cannot. In summary, for 
the overall control of Chagas transmission, we undoubt-
edly favoured the control of its main vector in Brazil, the 
domiciliated Triatoma infestans. We were enthusiastic 
about the perspectives of insecticide-based vector con-
trol after the results of a large-scale program pioneered 
by the state of São Paulo in the 1960s. In the 1970s, the 
scientific community battled for the implementation of 
a similar program on a national scale. At the Caxambu 
meetings, Brazil, A Prata, JR Coura, JC Pinto Dias and 
Z Brener, to mention a few, insisted on the need to con-
trol T. infestans as the best way available to control Cha-
gas disease. Carlos Chagas Filho and other scientists in-
terceded with the government. Documents and petitions 
circulated between scientists and government. I remem-
ber having given an interview to a Brazilian magazine 
of wide circulation saying that, with the money that the 
government used to buy one fighter jet, we could control 
Chagas disease. Well, the interview did not please the 
military but, as a sign of the changing times, they did not 
harass me as I expected. In fact, to be fair, the most lu-
cid among them were already committing themselves to 
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launch such a Chagas Control Program. In 1982, while 
we were writing our paper, the Brazilian program for the 
control of T. infestans was still in its infancy, but its ini-
tial successes were quite encouraging. We stressed this 
point in the paper and time proved that we were right. 
The current results are unquestionable: T. infestans has 
been eliminated or placed under control in Brazil (Dias 
1987, Silveira & Vinhaes 1999) and in the countries that 
adhered to the Southern Cone Initiative, except in Bolivia 
and in a few other South American foci (Schofield et al. 
2006). Human transmission of T. cruzi by T. infestans in 
Brazil has been curtailed after 30 years since the launch-
ing of the program (Massad 2008). However, in 1982 we 
were afraid that the program could suffer interruptions, 
opening the way to a dreaded re-colonisation of domi-
ciles by T. infestans (Dias & Schofield 1999). This did 
not happen. We were afraid that colonisation by sylvatic 
triatomines could follow as domiciles were vacated by 
T. infestans. This did not happen at a significant scale 
either, and wherever it began to happen it was rapidly 
circumvented. There was the potential danger that popu-
lations of sylvatic T. infestans living in the Bolivian val-
leys could invade human dwellings, jeopardising control 
programs in South America (Noireau et al. 2005).  As of 
today, there are no signs of such a phenomenon taking 
place (Cortez et al. 2007). As to the danger of the de-
velopment of significant triatomine resistance to BHC, 
the chemical industry was quick to provide alternative 
insecticides, such as synthetic pyrethroids with residual 
effects. After three decades, it became clear that insec-
ticide spraying, housing improvement and strict sanitary 
surveillance were indeed the best ways to curb T. cruzi 
domestic transmission, which had historically been the 
principal source of cases of Chagas disease in Brazil 
(Dias et al. 2002). 
Question 3 - In this scenario, would a vaccine be 
necessary? 
Yes, for at least three reasons. First, vaccines are the 
gold standard of prophylaxis for infectious diseases; they 
should be available for every infectious disease including 
Chagas disease, irrespective of any other reason. In addi-
tion, like other scientists, Brener and I fully appreciated 
the tremendous scientific challenge posed by a vaccine 
against Chagas disease and were very well aware of the 
considerable collateral amount of knowledge that could be 
gained from this saga regardless of its outcome. Moreover, 
in 1982 we did not know the results of the vector control 
program so we considered a vaccine necessary and essen-
tial if such a program failed in the immediate, as well as in 
the remote future. These reasons still prevail.
However, there is a problem today that we did not 
completely formulate in 1982, although I raised the issue 
on later occasions (Camargo 1984, 2000).The problem 
is: to whom would a Chagas vaccine be destined? Which 
population would be the target for a Chagas vaccine?
If we had had a vaccine on hand in 1982 we would 
have known exactly which population to vaccinate. In 
the 1980s, in Brazil alone, there were 25 million people 
at risk of infection. There were five million chagasic 
people and 120,000 new cases a year. Seropositivity for 
T. cruzi was 4.4% for the general population and 5% for 
children in the 0-4 years age group. Chagas disease in 
Brazil was present in an area of more than three million 
km2, including more than 2,400 municipalities. Today, 
except for the punctual explosions of oral infection cases 
(see item 5), there are no reports of new acute cases of T. 
cruzi infection. Seropositivity in children has dropped to 
0.12%. The number of T. infestans captured in domiciles 
all over Brazil dropped by 99.3% and, from the 2,400 
municipalities formerly infested, no more than 100 or so 
remain as unimportant foci. There is no defined popula-
tion at risk of infection (Dias 1987, Silveira & Vinhaes 
1999, Massad 2008).
Thus, there is no population candidate for a vac-
cine in Brazil at the moment. However, overall in the 
Americas, there are an estimated 16 million people still 
infected with T. cruzi and 50-80 million at risk. I cannot 
predict what is going to happen in the areas at risk, but 
programs similar to the Southern Cone Initiative are be-
ing carried out in Central America and in the Northern 
cone of South America. Bolivia as well is committed to 
a triatomine control program. Based on past experience 
in Brazil, we can foresee the success of these initiatives 
but, just in case, it would do no harm to have a vaccine.
Question 4 - What should be the requisites of a vac-
cine against Chagas disease?
The 1982 paper was not intended to deal with vector 
control, but with a vaccine for Chagas disease. Therefore, 
we proceeded to analyse the requisites that a vaccine 
should have. Our conclusions have changed little since.
Primum non nocere - Thirty years ago there were se-
rious concerns about antigen-induced autoimmunity and 
immunosuppression in Chagas disease. Accordingly, we 
expressed our fears about the potential inconveniencies 
of antigen-derived vaccines. Presently, although some 
controversy remains (Leon & Engman 2001, Kierszen-
baum 2003, Tarleton 2003, Hyland & Engam 2006), 
it seems that parasite presentation of antigens, that is, 
parasite persistence, is necessary to induce a focal in-
flammatory response (Tarleton 2001). The matter is still 
unsettled, but scientists nowadays are less scared by 
the spectre of autoimmunity. Thus, my original strong 
concerns about antigen-induced disease have subsided 
somewhat, although the “allergic“ myocarditis reported 
by Muniz (Muniz & Pena Azevedo 1947) after the in-
oculation of Rhesus monkeys with merthiolate-killed T. 
cruzi still causes me some unrest. This is because large 
parts of the arguments in favour of and against autoim-
munity have centred on experiments in mice. Primates 
have never been the object of experimental studies.
Sterile immunity - As we said in 1982: “A vaccine 
which merely attenuates the acute phase of the infection 
- a procedure possibly acceptable for other infectious 
diseases - would be of questionable value in Chagas 
disease.”. This was because there was no evidence that 
the mildness or severity of the acute phase was directly 
related to the onset and severity or mildness of chronic 
disease. Clinical records were full of reports on the lack 
of correlation between both phases (Brener & Andrade 
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1979). Mouse experimental models are inadequate to 
test this correlation, whereas rabbit, dog and monkey 
models have not properly coped with the problem. We 
were afraid that a few infective forms escaping a non-
sterilising vaccine could become responsible for a full 
course of chronic symptoms. For this reason, until the 
contrary was proved, we considered the sterilising requi-
site as absolutely mandatory. However, as mandatory as 
this precept seems to be, to date, the success of vaccina-
tion attempts remains measured by the mortality rates of 
mice in the acute phase of a challenging post-vaccinal 
infection. Most authors ignore or give little significance 
to residual patent or sub-patent parasitaemias that may 
lead to chronic infections. It has actually been shown in 
humans that parasite persistence in tissue foci is neces-
sary for chronic inflammation and disease (Vago et al. 
1996, Anez et al. 1999, Tarleton & Zhang 1999, Zhang & 
Tarleton 1999). Unfortunately, chronic evolution has not 
been properly evaluated in experimental models main-
ly because the most common experimental model, the 
mouse, is inadequate for that purpose. 
Effectiveness against all T. cruzi strains - In the paper 
to the Academy of Sciences of the Vatican we stressed 
the fact that there were diverse strains of T. cruzi and that 
a vaccine should be effective against them all. However, 
we did not know at the time the full extent of T. cruzi ge-
netic variability. Ever since, isoenzyme phenotyping and 
spliced leader gene and ribosomal genotyping revealed 
a considerable and ever-increasing number of lineages 
and hybrids (Miles et al. 1978, 2003, Souto et al. 1996, 
Brisse et al. 2000, Fernandes et al. 2001, Marcili et al. 
2009, unpublished observations). The antigenic makeup 
of these strains is unknown, whereas their immunogenic 
and pathogenic importance remains to be assessed. Is 
there a universally protective antigen? Until we know 
that, a question will remain unaddressed: would a vac-
cine produced against one strain be effective against all 
T. cruzi existing strains?
Question 5 - How to evaluate the effectiveness of a 
Chagas disease vaccine? 
The experimental model - In 1982, we stressed that 
the mouse model obviously was not an adequate experi-
mental model for Chagas disease. Three decades later, 
we still lack a widely adopted and satisfactory experi-
mental model for Chagas disease. The mouse is a handy 
and useful experimental model, but in many systems it 
is used only for “first approximations” to be followed 
by tests in more adequate models. This is the case, for 
instance, of drug screening for effects and toxicity; tro-
pism, infectivity and virulence of infectious agents; an-
tigens, antigen adjuvants and deliverers, and preliminary 
antibody and cell immune responses. Unfortunately, for 
Chagas disease, the mouse remained the sole model 
throughout the years. In Chagas, mice fail to mimic 
chronic disease as they fail to recognise T. cruzi anti-
gens that are important in the human immune response 
(Galili 1993, Galili & Andrews 1995). As we said be-
fore, and I submit here again, the dog is probably the best 
lab model for Chagas disease. In nature, dogs develop a 
human-like Chagas disease, both acute and chronic, and 
are found naturally infected in the most diverse biomes 
colonised by man. For these reasons, they are excellent 
epidemiological sentinels for T. cruzi vectorial transmis-
sion (Umezava et al. 2009, unpublished observations). 
The dog model has only recently been more deeply ex-
plored (Valadares et al. 2008, Guedes et al. 2008) and it 
has been shown that dogs respond to T. cruzi infection 
with the full cohort of factors and kinins that accompany 
the human infection (Guedes et al. 2009). I believe that 
dogs would be the model of choice for testing prospective 
vaccines, although I agree that it may be an inconvenient 
model for first approximations because of handling and 
nursing needs and the emotional objections of bystand-
ers and researchers alike.  
Diagnosis, vaccination and cure - The laboratory 
diagnosis of Chagas disease was no longer a problem 
in 1982. Serological diagnosis was ripe for the national-
scale epidemiological survey that preceded the launch-
ing of the Chagas control program in the 1980s (Camar-
go et al. 1984). However, serology could not distinguish 
between present and past infections. Ever since, efforts 
have been made to find serological (Krettli & Brener 
1976, Krettli 1980) or molecular markers of cure, but the 
problem persists. Without a diagnostic method with such 
capabilities, the actual effectiveness of a vaccine cannot 
be properly evaluated, not only in experimental models, 
but also in humans. As we said in 1982 and I reiterated 
at later opportunities (Camargo 1984, 2000), due to the 
silent and slow-evolving pathology of chronic Chagas, 
the evaluation of the effectiveness of a vaccine would 
take years. Thus, even if we had already overcome all 
laboratory and experimental barriers to developing a 
heroic vaccine capable of attenuating the acute phase, 
the field tests designed to assess whether such a vaccine 
could prevent chronic disease in man would take dec-
ades of clinical observation. It would take at least two 
or three decades, in the favourable (although unfortu-
nate) scenario that there was a population to vaccinate, 
as discussed in item 3. The situation has not improved 
since 1982 and it is dismaying to see that the molecular 
advances in the development of candidate antigens and 
vaccines have not been accompanied by the develop-
ment of experimental models for Chagas disease, nor by 
methods to ascertain its cure.
Question 6 - What is new?
New techniques, new scenarios, new problems - In 
1982, we registered 49 full papers on vaccination at-
tempts published in regular scientific journals and found 
more than 150 reports in Brazilian and Argentine meet-
ings alone. In these attempts, the antigens used were: 
“avirulent” or attenuated strains of T. cruzi; culture 
forms of non-pathogenic insect trypanosomatids; killed 
culture and blood forms and sub-cellular fractions and 
purified, cellular or cell-surface antigens of T. cruzi or 
other trypanosomatids. Such attempts may not have 
stopped but, apparently, editors have stopped publishing 
them. Exceptionally, one or another attempt with living 
trypanosomatids has reached the scientific press in re-
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cent times (Basso et al. 2008). Despite many optimistic 
claims by authors, all vaccination attempts failed to con-
fer sterile immunity. At best, they increased the survival 
rates or prevented the death of vaccinated animals after 
a T. cruzi virulent challenge. The animal model used 
was always the mouse, with three or four exceptions. 
Adjuvants were used sporadically. The vaccination and 
challenge routes were always sub-cutaneous or intra-
peritoneal in a few instances.
Things have changed in recent years. The DNA vac-
cine approach has taken over the scene. Initially, T. cruzi 
surface genes inserted in plasmids have been tested, 
but they also failed to induce sterile immunity in mice 
(Wizel et al. 1997, 1998, Costa et al. 1998, Boscardin et 
al. 1999). The choice of a plasmid stimulatory of Type I 
immunity as the vector for two surface genes induced 
total protection against a virulent challenge. The para-
sitaemia was null, but unfortunately the model used 
was the mouse, which provided information as a “first 
approximation” only (Machado et al. 2006). Proposed 
therapeutic vaccines represent a departure from the all-
or-none protection model. Since DNA vaccines are in 
principle capable of producing antigens for the duration 
of the life of the vaccinated mice, they represent a life-
long source of antigens that may induce protection or 
reduce the severity of the “disease” in mice, but only in 
mice (Garg & Tarleton 2002, Zapata-Estrella et al. 2006, 
Sanchez-Burgos et al. 2007).
An alternative form of vaccination, mucosal or oral 
vaccination (Hoft et al. 1996, Schnapp et al. 2002, Hoft 
& Eickhoff 2005), although tested with certain success 
in mice only, finds incidental support in the current epi-
demiology of Chagas in the sense that it may prevent 
mucosal penetration and proliferation of T. cruzi.
Presently, new acute cases of Chagas disease in Bra-
zil result from blood transfusion, trans-placental trans-
mission and oral infection. The latter form results from 
the accidental ingestion of grinded triatomines carrying 
T. cruzi originating from wild animals. Triatomines have 
been accidentally grinded with fruit in the preparation of 
juices of açai (a palm tree widespread in Amazonia) and 
sugar cane. Clearly accidental, these outbreaks of oral 
infection can occur anywhere in the country, but have 
been more frequent in Amazonia. The episodes usually 
strike dozens of people at once, are serious and often fa-
tal, but are always limited in space and time. There have 
not been more than 200 or 300 such outbreaks (Umeza-
wa et al. 1996, Cardoso et. al. 2006, Coura 2006, Aguilar 
et al. 2007, Roque et al. 2008, Valente et al. 2008).
Would an oral vaccine be of help in preventing these 
Chagas outbreaks? No. Even if it prevented mucosal in-
fection it would be of no use as a vaccine. This is be-
cause, again, we cannot define the population at risk. 
Finally, since vector control was effective in curbing 
Chagas transmission in Brazil and since vaccines cannot 
be used at the moment to prevent the current forms of 
Chagas transmission (transfusive, trans-placental or ac-
cidental), does this mean that a vaccine against Chagas 
disease is unnecessary?
No, it does not. It may be unnecessary for Brazil at the 
moment, but Chagas is still endemic in large segments of 
Central and South America where close to 100 million 
people are still at risk. Vector control programs are under 
way, but they depend on reliable sanitary services, eco-
nomic resources and political resolve. This is not a trivial 
conjunction of factors and even where they already co-
exist, political turmoil and economical crises may endan-
ger any vector control program that relies on stability. In 
contrast, vaccinated people will remain immune through 
political unrest, economic fluctuations and the not-un-
common episodes of public health failure.
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